Understanding Adolescent Anti‐Retroviral Therapy Use in the BREATHER‐Plus Trial: Qualitative Findings From South Africa and Uganda
Journal of the International AIDS Society · 2026
DOI: 10.1002/jia2.70207 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the International AIDS Society, 2026. Verfasst von Londiwe Shandu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Africa Health Research Institute, KwaZulu-Natal, South Africa. Hauptthemen laut MEDLINE: HIV Infections, Anti-Retroviral Agents, Medication Adherence, Anti-HIV Agents. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, European and Developing Countries Trial Partnership 2 programme.
Abstract (Originalsprache)
Introduction
The BREATHER‐Plus trial was an open‐label, randomized non‐inferiority trial comparing weekends off antiretroviral therapy (ART) (short cycle therapy [SCT]) with daily oral ART (continuous therapy [CT]) for adolescents aged 12–19 years. We present findings from the qualitative sub‐study on the factors influencing trial participants’ decisions to take/not take ART in accordance with their randomized arm.
Methods
Qualitative data collection was conducted in South Africa and Uganda from December 2022 to July 2024 using in‐depth interviews (IDIs) and focus group discussions (FGDs). We purposively recruited 29 trial participants (14 SCT/15 CT arm) to take part in IDIs in South Africa. From the trial sites in both countries, 47 trial participants, 17 non‐trial participants, 15 caregivers and 16 healthcare providers took part in FGDs. Data collection with trial participants focused on adherence to SCT compared to daily ART; the acceptability of SCT and the experience of taking part in the trial. All FGDs explored the feasibility of SCT and preferences for alternative approaches to accessing therapy. Data were analysed thematically.
Results
Both IDI and FGD data showed that the opportunity to have weekends off from treatment was welcomed by participants, caregivers and healthcare providers. However, the understanding of “2 days off” treatment was interpreted flexibly by some participants. Trial participants in both arms described their fluctuating adherence practices both prior to and during the trial. The introduction of SCT as a possibility through the trial prompted some to talk about previously concealed missed doses. Participants reported that they only mentioned missed doses in the clinic if they had a raised viral load result or had returned to the clinic with too many pills. Many participants relied on their viral load result to confirm that non‐adherent behaviour was not problematic.
Conclusions
Our findings offer insights into the factors that shape ART adherence among adolescents living with HIV. Adherence is not a static behaviour but a socially embedded and relational practice, shaped by adolescents’ interpretations of treatment, interpersonal relationships and the structure of care environments. Regimen modification alone does not resolve the broader social and emotional challenges adolescents face.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Africa Health Research Institute, KwaZulu-Natal, South Africa.
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
- School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.
- Department of Psychiatry, University of Oxford, Oxford, UK.
- Enhancing Care Foundation, Department of Paediatrics and Children Health, Victoria Mxenge Hospital, University of KwaZulu-Natal, Durban, South Africa.
- Joint Clinical Research Centre, Kampala, Uganda.
ORCID-Profile: Londiwe Shandu, Stella Namukwaya, Tamlyn Carmin Seunanden, Nothando Ngwenya, Moherndran Archary, Cissy Kityo, Deborah Ford, Sarah L Pett, Adeodata R Kekitiinwa, Sarah Bernays, Janet Seeley
Förderung
- Wellcome Trust
- Medical Research Council
- European and Developing Countries Trial Partnership 2 programme
Zitieren
APA
Shandu, L., Namukwaya, S., Seunanden, T. C., Ngwenya, N., Archary, M., Kityo, C., Ford, D., Pett, S. L., Kekitiinwa, A. R., Bernays, S., Seeley, J., & BREATHER‐Plus trial team (2026). Understanding Adolescent Anti‐Retroviral Therapy Use in the BREATHER‐Plus Trial: Qualitative Findings From South Africa and Uganda. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.70207
Vancouver
Shandu L, Namukwaya S, Seunanden TC, Ngwenya N, Archary M, Kityo C, et al. Understanding Adolescent Anti‐Retroviral Therapy Use in the BREATHER‐Plus Trial: Qualitative Findings From South Africa and Uganda. Journal of the International AIDS Society. 2026. doi:10.1002/jia2.70207
BibTeX
@article{Shandu2026,
author = {Shandu, Londiwe and Namukwaya, Stella and Seunanden, Tamlyn Carmin and Ngwenya, Nothando and Archary, Moherndran and Kityo, Cissy and Ford, Deborah and Pett, Sarah L and Kekitiinwa, Adeodata R and Bernays, Sarah and Seeley, Janet and BREATHER‐Plus trial team, BREATHER‐Plus trial team},
title = {Understanding Adolescent Anti‐Retroviral Therapy Use in the BREATHER‐Plus Trial: Qualitative Findings From South Africa and Uganda},
journal = {Journal of the International AIDS Society},
year = {2026},
doi = {10.1002/jia2.70207}
}
EUVIMED